Monitor the stockholder meeting within 75 days for approval of the convertible note shares — failure to obtain approval could trigger adverse conversion terms. Also watch for integration updates on Helomics' revenue contribution and any subsequent capital raises given the anti-dilution clause in the note.
Price Chart
Executive Summary
DataMeds AI acquired Helomics Corporation from Axe Compute for $1.5 million total consideration, consisting of 636,328 shares (19.99% of outstanding common stock) and a $1,363,672 convertible promissory note. The acquisition adds a CLIA/CAP-certified cancer diagnostics lab and CRO business, along with $1.5 million in cash, with no third-party debt. The deal closed simultaneously on September 11, 2026, and Helomics became a wholly owned subsidiary.
Key Financial Metrics
Key Facts
- DataMeds AI acquired Helomics Corporation from Axe Compute Inc. for total consideration of $1.5 million.
- Consideration comprised 636,328 shares of DataMeds common stock (19.99% of outstanding pre-deal) and a $1,363,672 convertible promissory note.
- Convertible note bears 7% simple interest, matures September 11, 2029, and is convertible at $1.00 per share subject to stockholder approval.
- Helomics came with $1.5 million in cash, no third-party debt, and no outstanding unpaid accounts payable beyond ongoing monthly expenses.
- Seller agreed to a 12-month lock-up on consideration shares and a 6-month voting agreement to vote with DataMeds board.
- DataMeds must seek Nasdaq stockholder approval within 75 days for issuance of shares upon conversion of the note.
- The acquisition expands DataMeds into oncology diagnostics and precision medicine, adding a CLIA/CAP-certified lab and CRO business.
Financial Impact
Total deal value of $1.5 million, with $1,363,672 in convertible debt and 636,328 shares representing 19.99% dilution. Helomics contributed $1.5 million cash at closing, effectively making the net cash outlay zero.
Risk Factors
- Potential dilution from conversion of the $1,363,672 note at $1.00/share, which could add up to 1,363,672 shares if fully converted.
- Anti-dilution provision in the convertible note could lower conversion price if DataMeds issues shares below $1.00, increasing potential dilution.
- Integration risk of Helomics' oncology lab and CRO business into DataMeds' existing health IT platform.
- Nasdaq listing requirement for stockholder approval adds execution risk and timeline pressure.
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-042951 |
| Exhibit: ex4-1.htm | 0001493152-26-042951 |
| Exhibit: ex99-1.htm | 0001493152-26-042951 |
| Document: form8-k.htm | 0001493152-26-042951 |
| Document: 0001493152-26-042951-index-headers.html | 0001493152-26-042951 |
| Document: 0001493152-26-042951-index.html | 0001493152-26-042951 |
| Document: 0001493152-26-042951.txt | 0001493152-26-042951 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $2.15 | awaiting T+20 | — | $2.06 (+4.19%) |
Oct 20, 2026 7d ago | 8-K | $2.75 | awaiting T+20 | — | $2.06 (−25.09%) |
Oct 16, 2026 11d ago | 8-K | $2.67 | awaiting T+20 | — | $2.06 (−22.85%) |
Oct 13, 2026 14d ago | 8-K | $2.85 | awaiting T+20 | — | $2.06 (−27.72%) |
Sep 17, 2026 5w ago | 8-K | $3.76 $2.63 | ▼ −30.05% | ▼ −30.26% | $2.06 (−45.21%) |
Sep 16, 2026 5w ago | 8-K | $4.64 $2.85 | ▼ −38.58% | ▼ −39.78% | $2.06 (−55.60%) |
Aug 18, 2026 10w ago | 8-K | $1.38 $6.07 | ▼ −339.86% | ▼ −341.60% | $2.06 (−49.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers